Dr Anoop Shah: key facts
- Kind of voice
- Academic
- Role
- Professor of Cardiovascular Medicine at LSHTM
- Quoted on
- Heart disease & stroke, Diabetes
- Tracked press citations
- 2
- Most recently quoted
- 30 Sept 2026
- First quoted
- 10 Sept 2026
“This study highlights how patterns of cardiovascular disease shifted in England during and after the COVID-19 pandemic. Notably, the burden of major cardiovascular conditions was higher among individuals from disadvantaged socioeconomic backgrounds and certain ethnic minority groups. We need to address these health disparities to reduce the overall burden of cardiovascular disease.”
What Dr Anoop Shah has said
“Clinical trials often recruit highly selected populations so their findings do not always generalise to the typical person living with type 2 diabetes. Our real-world analysis fills an important evidence gap and supports broader use of SGLT-2 inhibitors in clinical practice.”
UCL Institute of Health Informatics · Diabetes · 10 Sept 2026 · Wider use of SGLT-2 inhibitors in diabetes ‘could prevent 20,000 deaths a year’, say researchers ↗
Where Dr Anoop Shah has been quoted
- Study reveals widening heart disease inequalities in England after the COVID-19 pandemiclshtm.ac.uk · 30 Sept 2026
- Wider use of SGLT-2 inhibitors in diabetes ‘could prevent 20,000 deaths a year’, say researcherspulsetoday.co.uk · 10 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.